| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
GNTA Stock Overview
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
Genenta Science S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.30 |
| 52 Week High | US$13.13 |
| 52 Week Low | US$5.11 |
| Beta | 0 |
| 1 Month Change | -2.33% |
| 3 Month Change | 5.35% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -42.73% |
Recent News & Updates
Gene therapy developer Genenta Science named a buy at Wainwright on tumor approach
H.C. Wainwright has initiated stem cell gene therapy developer Genenta Science (NASDAQ:GNTA) as a buy seeing promise for the company's technology providing advantages differentiating elements over other cellular therapies for cancer. The firm has a $25 price target (269% upside based on Friday's close). Genenta shares are down 9% in early Monday afternoon tradig. Analyst Emanuela Branchetti said that the company's technology is "based on the ex-vivo lentiviral vector (LVV) mediated modification of autologous hematopoietic stem/progenitor cells (HSPCs) that deliver immunomodulatory molecules directly to the tumor." She highlighted four advantages/differentiating factors of Genenta's (GNTA) tech: 1. It focuses on a type tumor-associated myeloid cells (TEMs) that known to be involved in promoting angiogenesis and tumor growth; 2. It is built in a way that controls transgene expression and avoids off-target and systemic toxicity; 3. It has potential for long-tern durabiklity given the use of HSPCs; and 4) It is agnostic so it could potentially be used in a wide variety of cancers. Genenta's (GNTA) lead candidate, temferon, is currently in phase 1/2a for glioblastoma multiforme. It is idesigned to deliver IFN-α only at the tumor site. A data update is expected in this half of the year with enrollment completion in H1 2023. A phase 2 study is planned for H2 2023.
Is Genenta Science (NASDAQ:GNTA) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Shareholder Returns
| GNTA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.2% | 1.2% | 3.2% |
| 1Y | n/a | -21.7% | -10.1% |
Return vs Industry: Insufficient data to determine how GNTA performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how GNTA performed against the US Market.
Price Volatility
| GNTA volatility | |
|---|---|
| GNTA Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: GNTA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: GNTA's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 4 | Pierluigi Paracchi | https://www.genenta.com |
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company’s lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
Genenta Science S.p.A. Fundamentals Summary
| GNTA fundamental statistics | |
|---|---|
| Market Cap | €111.93m |
| Earnings (TTM) | -€5.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-20.2x
P/E RatioIs GNTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNTA income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €5.53m |
| Earnings | -€5.53m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.30 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did GNTA perform over the long term?
See historical performance and comparison